Four-price HPV half-year sales of 2.62 million Zhifei biological net profit increased 297%

On the evening of August 13, Zhifei Bio released its 2018 half-year results, reporting that the company achieved operating income of RMB2,072 million in the first half of the year, up 365.42 percent from the same period last year;
Currently, there are five autonomous products on sale, including AC-Hib vaccine, ACYW135 polysaccharine vaccine, Hib vaccine, AC brain polysaccharine binding vaccine, microcard;
for Zhifei Bio, this year's focus is on the company's agent sales of HPV vaccine in the domestic market. According to the data, in November 2017, the company's agent mersa east four-price HPV was issued, and in May 2018, the company received the State Drug Administration issued a nine-price HPV vaccine "biological products approval certificate."
reporting period, Zhifei Bio vigorously carried out the sale of imported agent products represented by the four-price HPV vaccine. Up to now, four-price HPV has been in the country's 29 provincial units winning the bid, promotion, sales work is also under way.
In addition, the five-priced rotisse vaccine has been awarded in two provincial units since it was issued on April 19, 2018, and the nine-price HPV vaccine has been awarded in five provincial units since the signing of the supplementary agreement on May 1, 2018.